H.C. Wainwright initiated coverage of CervoMed (CRVO) with a Buy rating and $42 price target The company’s lead asset neflamapimod is currently in Phase 2b development for dementia with Lewy bodies, the analyst tells investors in a research note. The firm says CervoMed is combating an area of significant unmet need in neurology with a mechanistically and clinically differentiated lead candidate.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.